|
KMID : 0856920090120040194
|
|
Journal of Hospice and Palliative Care
2009 Volume.12 No. 4 p.194 ~ p.198
|
|
|
Effect of Octreotide on Patients with Malignant Bowel Obstruction
|
|
Park Ji-Chan
Jang Yi-Sun
Jeon Eun-Kyoung
Kim Dong-Kyu
Lee Wook-hyun
Lee Guk-Jin
You Si-Young
Choi Hyun-Ho
Park Suk-Young
|
|
|
Abstract
|
|
|
|
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea Purpose: Malignant bowel obstruction causes gastrointestinal symptoms and leads to diminished quality of life in patients with advanced cancer. Several studies have shown the efficacy of octreotide for the relief of malignant bowel obstruction-related symptoms. The aim of this study is to assess the efficacy and safety of octreotide in patients with malignant bowel obstruction. Methods: We retrospectively reviewed medical records of twenty nine patients who had suffered from malignant bowel obstruction without clinical improvement of conservative care and subsequently, received octreotide treatment. Initial dosage of octreotide was 0.1 mg/day, and dose was escalated depending on the clinical effect. For each patient, we assessed visual analogue scale (VAS) of pain, number of vomiting episode, and amount of nasogastric tube drainage. Results: Median dosage of octreotide was 0.2 mg/day (range 0.1~0.6), and median duration from initial medication to death was 20 days (range 2~103). VAS before and after octreotide treatment were 5.61.24, and 2.70.96, respectively. The numbers of vomiting episode before and after octreotide treatment were 3.6/day2.5, and 0.4/day0.8, respectively. The mean amounts of nasogastric tube drainage before and after octreotide treatment were 9751,083 cc/day and 115196 cc/day, respectively. Statistically significant reduction in VAS, the number of vomiting episode and the amount of nasogastric tube drainage were observed after octreotide treatment (P<0.05). Conclusion: Administration of octreotide in patients with malignant bowel obstruction, which is uncontrolled by other medication, was effective and safe. In such clinical situations, physicians should consider to add of octreotide for symptomatic control.
|
|
|
KEYWORD
|
|
|
Octreotide, Intestinal obstruction, Neoplasms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|